RxDoctor Payments Data

Jignesh Patel, MD

Internal Medicine · St Augustine, FLNPI 1487693636

Payments from drug & device makers

$703in general payments, 2019–2025

Across 13 payments — averaging $54.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$306
  • Amgen$124
  • E.r. Squibb & Sons, L.L.C.$120
  • Boston Scientific$100
  • AstraZeneca$31
  • Medtronic$22

What the payments were for

  • Food & beverage$703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)7$306
Amgen1$124
E.r. Squibb & Sons, L.L.C.1$120
Boston Scientific1$100
AstraZeneca2$31
Medtronic1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$703 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$593,371
Medicare patients
680
Services billed
7,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban470$167,283
JanuviaSitagliptin Phosphate56$33,342
XareltoRivaroxaban60$32,360
JardianceEmpagliflozin55$23,372
MyrbetriqMirabegron91$21,145
EntrestoSacubitril/Valsartan57$16,846
MicafunginMicafungin Sodium28$13,616
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,377
Atorvastatin Calcium612$9,552
Levothyroxine Sodium434$7,986
Incruse ElliptaUmeclidinium Bromide20$7,610
Gabapentin325$6,641
Potassium Chloride294$6,374
GlatopaGlatiramer Acetate14$6,177
TrulicityDulaglutide11$6,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$306$32,36060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →